Menin Inhibition Shows Utility in Heterogenous AML Population

According to findings presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, revumenib (Revuforj) showed feasibility following allogeneic stem cell transplantation among patients with heavily pretreated acute myeloid leukemia (AML). The data appeared favorable compared with historical cohorts, supporting the prospective assessment of menin inhibition as maintenance therapy in this population.

In a conversation with CancerNetwork^® at the meeting, presenting investigator Hannah Goulart, MD, a hematology oncology fellow at MD Anderson Cancer Center, discussed the clinical implications of these findings. She noted that the inclusion of both adult and pediatric patients in a “very heterogenous cohort” affirmed the potential to broadly administer menin inhibitors in this treatment setting. Additionally, she emphasized collaboration with different multidisciplinary team members at academic sites and community centers to ensure safe mitigation of toxicities like thrombocytopenia and effective post-transplant monitoring.

Transcript:

CancerNetwork: What do these findings suggest about the potential role of menin inhibition in AML, especially following allogeneic stem cell transplantation?

The data that we have gained from this study is that we are able to broadly administer menin inhibitors [after] transplant in a very heterogeneous cohort. One of the strengths from our study is that we included pediatric patients in addition to adult patients. Historically, many trials just included adult patients. The fact that we're able to safely administer this in the pediatric setting really broadens the applicability of our results, and that's important for these patients who, historically, are [at a] very high risk of relapse.

How can clinicians collaborate with colleagues from the transplant unit and other multidisciplinary team members to effectively sustain quality of life as patients undergo treatment with transplantation and revumenib?

Continuing to collaborate with the leukemia and transplant doctors at academic sites and in communities so that they can closely monitor for the potential [adverse] effects, namely the thrombocytopenia, but as long as the patients are closely monitored in that immediate post-transplant space when they're initiating revumenib is the most important thing. [It's about] having the open line of communication.

Reference

Goulart H, Okeleji O, DiNardo CD, et al. Revumenib as maintenance for AML following allogeneic stem cell transplantation. J Clin Oncol. 2026;44(suppl 16):6505. doi:10.1200/JCO.2026.44.16_suppl.6505